BioXcel Therapeutics, Inc. (BTAI) Discussion of Managing Acute Agitation in Schizophrenia and Bipolar Disorders at Home Transcript [Seeking Alpha]
Award-Winning Journalist Anjalee Khemlani to Host Virtual Roundtable with Leading Medical Experts to Discuss Latest Developments in Treating Acute Agitation Related to Neuropsychiatric Conditions
Looking at the Narrative for BioXcel Therapeutics After Fair Value Reset and Clinical Milestones [Yahoo! Finance]
BioXcel Therapeutics GAAP EPS of -$2.18 misses by $0.84 [Seeking Alpha]
BioXcel Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on Late-Stage Clinical Programs for Agitation in Bipolar, Schizophrenia, and Alzheimer’s Disease